Abstract 189P
Background
Tertiary lymphoid structures (TLSs) are lymphocyte aggregates that correlate with better prognosis in most cancers. TLSs possess anti-tumor potentials but their compositions and functions vary across cancer types and stages, so our understanding of TLS remains largely descriptive. Current studies are limited to fixed pathological samples for immunohistochemistry or spatial transcriptomics, yielding restricted mRNA content in rare cell types. To study the anti-tumor role of TLS, we choose prostate cancer, cause of one of the highest cancer-related deaths in U.S, as our disease model. Castration-resistant prostate cancer (CRPC) is a devastating disease state with high mortality and limited treatment options, including immune checkpoint therapy (ICT). Due to the positive correlation between TLS and ICT response, we want to promote the anti-tumor potentials of TLS in CRPC.
Methods
We aim to develop a region-specific in situ labeling methodology to capture live TLS cells in CRPC mice for characterizations. Since loss of PTEN is a common mutation in prostate cancer, we employed PB-Cre+;Ptenloxp/loxp mice to elucidate TLS composition and function in CRPC. Through photocatalytic labeling in tissue sections, we covalently tagged biotin to live TLS cells, followed by biotin+ TLS isolation for single-cell RNA sequencing (scRNA-seq) analysis.
Results
Our region-specific labeling method is validated in cell lines and tissue sections, including germinal center (GC) enrichment. Our study identified key clusters within CRPC TLS, including CD8+T, follicular helper T (Tfh), GC B, Mki67+ T/B cells and Naaa+ dendritic cells (DCs), among others. TLS also enriched for certain clones in TCR/BCR repertoires.
Conclusions
Through photocatalytic covalent labeling with biotin, we achieved image-guided labeling of live TLS cells for scRNA-seq and identified TLS-enriched cells with potential functions in antigen presentation, cytotoxicity and antibody secretion. We anticipate detecting changes in TLS signatures and functions following PI3K drug treatment, enabling a comprehensive analysis of TLS. Moreover, we plan to refine our methodology to expand the scope of application in other crucial biomedical research areas.
Legal entity responsible for the study
Peking University.
Funding
Peking University; Shenzhen Bay Laboratory.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract